$RNAZ

$1.67 -$0.04 (2.08%) Close

$RNAZ Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 16.9M shares outstanding

Who owns RNAZ?

By type of holder

Institutions 0.2% Insiders 0.0% Everyone else 99.8%

Concentration Top 10 holders own 83.9%

CK Life Sciences Int'l., (Holdings) Inc. 83.5% · Thomas Joseph Tracy 0.2%

Institutional ownership

0.2%

0.0 pts vs last qtr

Institutional holders

0 vs last qtr

Net shares bought

+2.6K

by institutions in Q2 2026

New / sold out

2 / 2

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Yorkville Advisors Global, LP NEW +19.6K
FMR LLC NEW +706

Biggest sellers in Q2 2026

Geode Capital Management, LLC SOLD OUT −12.7K
UBS Group AG −5.4K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Transcode Therapeutics Inc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2024–FY2025

+5392.2%

+5392.22% a year

Each share's claim on the business

−98.2%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $2.19M

over 2 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years2% Under 1 year98%

Quarterly turnover

63.1%

of institutional shares changed hands

Top 10 managers, median time held

1 quarter

Super Investors

Investment managers reporting RNAZ on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
YA Yorkville Advisors Global, LP	19.6K	0.12%	NEW	Q2 '26	0.1%
Shares held by quarter Peak holding19.6K (Q2'26) Change over 8 quarters+19.6K Share of the company0.120% Yorkville Advisors Global, LP's full portfolio →
GC Geode Capital Management, LLC	—	—	SOLD OUT	—	0.0%
Shares held by quarter Peak holding12.7K (Q1'26) Change over 8 quarters0 Geode Capital Management, LLC's full portfolio →

Yorkville Advisors Global, LP

19.6K

% of company

0.12%

Change vs last qtr

NEW

Held since

Q2 '26

Geode Capital Management, LLC

—

% of company

—

Change vs last qtr

SOLD OUT

Held since

—

8 more super investors behind a free account

See every manager holding Transcode Therapeutics Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting RNAZ on Form N-PORT; together they hold 0.1% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VE Vanguard Extended Market Index Fund Vanguard Index Funds	$40.6K	6.5K	0.04%	0.00%	June 30, 2026
FE Fidelity Extended Market Index Fund Fidelity Concord Street Trust	$10.7K	5.1K	0.03%	0.00%	August 31, 2026

Vanguard Extended Market Index Fund

Vanguard Index Funds

Position value

$40.6K

% of company

0.04%

% of the fund

0.00%

As of

June 30, 2026

Fidelity Extended Market Index Fund

Fidelity Concord Street Trust

Position value

$10.7K

% of company

0.03%

% of the fund

0.00%

As of

August 31, 2026

3 more funds behind a free account

See every fund holding Transcode Therapeutics Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
CL CK Life Sciences Int'l., (Holdings) Inc. 5%+ holder 13D · 83.9%	14.1M	83.48%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company83.480% Disclosed stake13D · 83.9% View the 13D/G filing →
TJ Thomas Joseph Tracy 5%+ holder 13D · 5.0%	35.0K	0.21%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company0.210% Disclosed stake13D · 5.0% View the 13D/G filing →

CK Life Sciences Int'l., (Holdings) Inc.

5%+ holder13D · 83.9%

14.1M

% of company

83.48%

Change vs last qtr

—

Held since

—

Thomas Joseph Tracy

5%+ holder13D · 5.0%

35.0K

% of company

0.21%

Change vs last qtr

—

Held since

—

Comments